Indian firm wins FDA approval for superbug antibiotic

Indian firm wins FDA approval for superbug antibiotic — Glenmark Pharmaceuticals receives US FDA nod for its novel antibiotic, marking a breakthrough in treating drug-resistant infections. The approved drug targets serious bacterial infections with limited treatment options. This paves the way for US market entry and potential revenue growth. Approval underscores India’s rising role in global pharma innovation.

📊 STOCKS: GLENMARK | 🏢 SECTOR: Pharma | #HIGHIMPACT #FDA